UK markets close in 7 hours 51 minutes

Marinus Pharmaceuticals, Inc. (MRNS.MX)

Mexico - Mexico Delayed price. Currency in MXN
Add to watchlist
124.000.00 (0.00%)
At close: 10:22AM CST
Currency in MXN

Valuation measures4

Market cap (intra-day) 1.42B
Enterprise value 785.19M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)14.35
Price/book (mrq)7.43
Enterprise value/revenue 1.65
Enterprise value/EBITDA -615.80

Trading information

Stock price history

Beta (5Y monthly) 1.14
52-week change 349.40%
S&P500 52-week change 322.26%
52-week high 3214.05
52-week low 383.00
50-day moving average 3125.02
200-day moving average 3128.46

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 554.93M
Implied shares outstanding 671.44M
Float 837.75M
% held by insiders 10.97%
% held by institutions 1104.50%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:4
Last split date 323 Sept 2020

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-466.48%

Management effectiveness

Return on assets (ttm)-46.11%
Return on equity (ttm)-423.43%

Income statement

Revenue (ttm)28.29M
Revenue per share (ttm)0.51
Quarterly revenue growth (yoy)-26.00%
Gross profit (ttm)N/A
EBITDA -129.39M
Net income avi to common (ttm)-145.34M
Diluted EPS (ttm)-44.95
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)113.25M
Total cash per share (mrq)2.06
Total debt (mrq)112.51M
Total debt/equity (mrq)N/A
Current ratio (mrq)3.07
Book value per share (mrq)-0.30

Cash flow statement

Operating cash flow (ttm)-113.98M
Levered free cash flow (ttm)-63.64M